Research programme: CNS disorders therapeutics - Sage Therapeutics

Drug Profile

Research programme: CNS disorders therapeutics - Sage Therapeutics

Alternative Names: Fragile X syndrome (FXS) therapy - Sage Therapeutics; PANAM platform - Sage Therapeutics; SAGE 105; SAGE 904; SAGE-689; SGE-202; SGE-301; SGE-516

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sage Therapeutics
  • Developer SAGE Therapeutics
  • Class Antidementias; Antidepressants; Antiepileptic drugs; Antipsychotics; Small molecules; Steroids
  • Mechanism of Action GABA A receptor modulators; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dementia; Dravet syndrome; Neurological disorders; Psychotic disorders; Rett syndrome; Seizures
  • No development reported Autistic disorder; Brain injuries; Depressive disorders; Fragile X syndrome; Multiple sclerosis; Pain; Post-traumatic stress disorders; Schizophrenia; Status epilepticus

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Fragile-X-syndrome in USA
  • 08 Jan 2018 Preclinical trials in Neurological disorders in USA (unspecified route)
  • 08 Jan 2018 Sage Therapeutics initiated IND-enabling studies for SAGE 904 before January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top